Larimar Therapeutics (LRMR) Research & Development (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Research & Development for 14 consecutive years, with $28.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 19.82% year-over-year to $28.0 million; the trailing twelve-month figure through Jun 2026 stood at $155.7 million (up 71.87% YoY), and the FY2025 full-year result was $154.2 million, up 110.46% from the prior year.
• Research & Development eased to $28.0 million in Q2 2026 per LRMR's latest filing, from $59.4 million in the prior quarter.
• Across five years, Research & Development topped out at $59.4 million in Q4 2025 and bottomed at $4.6 million in Q1 2023.
• Historically, Research & Development has averaged $18.1 million across 5 years, with a median of $12.9 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development slumped 60.21% in 2022, then jumped 235.01% in 2024.
• Over 5 years, Research & Development stood at $7.2 million in 2022, then soared by 47.52% to $10.6 million in 2023, then soared by 151.11% to $26.7 million in 2024, then surged by 122.05% to $59.4 million in 2025, then plunged by 52.84% to $28.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $28.0 million, $59.4 million, and $44.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.